Australia · Delayed Price · Currency is AUD Neurotech International Company Description
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia.
The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute-onset neuropsychiatric syndrome, and Rett syndrome.
It also engages in executing medical research projects; and developing technological devices. The company conducts clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary cannabis strains.
The company has a collaboration with The University of Sydney. Neurotech International Limited was incorporated in 2016 and is based in Melbourne, Australia.
| Country | Australia |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Anthony Filippis |
Contact Details
Address: 55 Collins Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9498 3132 |
| Website | neurotechinternational.com |
Stock Details
| Ticker Symbol | NTI |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000NTI9 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Peter James Lawrence Griffiths B.Sc. | Chief Executive Officer of AAT Research Ltd |
| Dr. Anthony Filippis M.B.A., Ph.D. | MD, Chief Executive Officer and Director |
| Associate Prof. Carolyn Ellaway | Chief Medical Officer |
| Dr. Bonni Goldstein M.D. | Chief Medical Advisor for USA |
| Alessandra Marie Gauvin | Company Secretary |